Long-acting version of Baxter's hemophilia drug succeeds in study
August 21, 2014 at 10:41 AM EDT
Aug 21 (Reuters) - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.
